Clinical-stage biopharmaceutical company Mirati Therapeutics and Incyte have entered into a clinical trial collaboration and supply agreement to study two drug combinations to treat patients with solid tumors. 

The two drug candidates INCB99280, a small molecule drug targeting the PD-L1 inhibitor, and adagrasib, targeting KRAS selective inhibitor, will undergo clinical trials to investigate the drug combination as a treatment for patients with solid tumors. Under the terms of the agreement, Incyte will fund Phase 1/1b of the combination study while Mirati will supply its drug, adagrasib, for the study. 

Global biopharmaceutical company Incyte develops and commercializes therapies in areas such as oncology, inflammation, and autoimmunity. The company has multiple targets in clinical development consisting of small molecules, monoclonal antibodies, and bispecific antibodies.